Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
September 03, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Begins Treatment of First Patients in its Phase 2a Alzheimer’s and Parkinson’s Trial
September 01, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Actively Recruiting Patients for its Phase 2a Trials in Alzheimer’s and Parkinson’s Diseases
August 20, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio CEO Appears on Executive Leaders Radio Program
July 23, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., July 23, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio CEO to Present the Company’s Novel Approach to Treating Parkinson’s Disease at University of Pennsylvania
July 20, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., July 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson’s and Alzheimer’s Patients
July 07, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Announces Positive Results from NIH Funded Chronic Toxicology Study
June 16, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., June 16, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio to Present at the June 2020 Virtual Summer Investor Summit
June 09, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., June 09, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Issued European Patent for Method of Treating Alzheimer’s Disease with ANVS401
June 02, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio 2020 Annual Meeting of Stockholders to Be Held on June 3, 2020
June 01, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., June 01, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...